Effects of d-amphetamine and fenfluramine on feeding pattens and activity of obese and lean Zucker rats

TPH2 in the Dorsal Raphe Nuclei Regulates Energy Balance in a Sex-Dependent Manner

AbstractCentral 5-hydroxytryptamine (5-HT), which is primarily synthesized by tryptophan hydroxylase 2 (TPH2) in the dorsal Raphe nuclei (DRN), plays a pivotal role in the regulation of food intake and body weight. However, the physiological functions of TPH2 on energy balance have not been consistently demonstrated. Here we systematically investigated the effects of TPH2 on energy homeostasis in adult male and female mice. We found that the DRN harbors a similar amount of TPH2+ cells in control male and female mice. Adult-onset TPH2 deletion in the DRN promotes hyperphagia and body weight gain only in male mice, but not in female mice. Ablation of TPH2 reduces hypothalamic pro-opiomelanocortin (POMC) neuronal activity robustly in males, but only to a modest degree in females. Deprivation of estrogen by ovariectomy (OVX) causes comparable food intake and weight gain in female control and DRN-specific TPH2 knockout mice. Nevertheless, disruption of TPH2 blunts the anorexigenic effects of exogenous estradiol (E2) and abolishes E2-induced activation of POMC neurons in OVX female mice, indicating that TPH2 is indispensable for E2 to activate POMC neurons and to suppress appetite. Together, our study revealed that TPH2 in the DRN contributes to energy balance regulation in a sexually dimorphic manner.

Does activation of midbrain dopamine neurons promote or reduce feeding?

BACKGROUND

Dopamine (DA) signalling in the brain is necessary for feeding behaviour, and alterations in the DA system have been linked to obesity. However, the precise role of DA in the control of food intake remains debated. On the one hand, food reward and motivation are associated with enhanced DA activity. On the other hand, psychostimulant drugs that increase DA signalling suppress food intake. This poses the questions of how endogenous DA neuronal activity regulates feeding, and whether enhancing DA neuronal activity would either promote or reduce food intake.

METHODS

Here, we used designer receptors exclusively activated by designer drugs (DREADD) technology to determine the effects of enhancing DA neuronal activity on feeding behaviour. We chemogenetically activated selective midbrain DA neuronal subpopulations and assessed the effects on feeding microstructure in rats.

RESULTS

Treatment with the psychostimulant drug amphetamine or the selective DA reuptake inhibitor GBR 12909 significantly suppressed food intake. Selective chemogenetic activation of DA neurons in the ventral tegmental area (VTA) was found to reduce meal size, but had less impact on total food intake. Targeting distinct VTA neuronal pathways revealed that specific activation of the mesolimbic pathway towards nucleus accumbens (NAc) resulted in smaller and shorter meals. In addition, the meal frequency was increased, rendering total food intake unaffected. The disrupted feeding patterns following activation of VTA DA neurons or VTA to NAc projection neurons were accompanied by locomotor hyperactivity. Activation of VTA neurons projecting towards prefrontal cortex or amygdala, or of DA neurons in the substantia nigra, did not affect feeding behaviour.

CONCLUSIONS

Chemogenetic activation of VTA DA neurons or VTA to NAc pathway disrupts feeding patterns. Increased activity of mesolimbic DA neurons appears to both promote and reduce food intake, by facilitating both the initiation and cessation of feeding behaviour.

Evidence for the Association of a Deleted Variant in the 5'-Flanking Region of the Chicken serotonin transporter (5-HTT) Gene with a Temporary Increase in Feed Intake and Growth Rate

The serotonergic system has been shown to be implicated in the regulation of mood and feeding behavior. Previous studies have identified a polymorphism in the 5'-flanking region of the serotonin transporter ( 5 - HTT ) gene of Lohmann Brown (LB) laying hens. The deleted variant D was found to be associated with increased body weight. The objective of this study was to address whether the increased body weight may be due to an increased feed intake. After hatching, hens were kept under ad libitum feeding conditions, and their body weight and feed intake were weekly determined. From 5 weeks of age, the body weight of hens with the D/D and W/D genotypes was significantly greater than that of W/W carrying hens. Interestingly, we found that the feed intake of D/D carrying hens, relative to body weight, was transiently increased only between 4 and 7 weeks of age ( p < 0.05), leading to a higher growth rate ( p < 0.05), compared with that of W/W carrying hens. These results suggest that the presence of variant D may be correlated with a transiently increased appetite of D/D carrying hens.

Diet-induced obesity and diet-resistant rats: differences in the rewarding and anorectic effects of D-amphetamine

RATIONALE

Obesity is a leading public health problem worldwide. Multiple lines of evidence associate deficits in the brain reward circuit with obesity.

OBJECTIVE

Whether alterations in brain reward sensitivity precede or are a consequence of obesity is unknown. This study aimed to investigate both innate and obesity-induced differences in the sensitivity to the effects of an indirect dopaminergic agonist.

METHODS

Rats genetically prone to diet-induced obesity (DIO) and their counterpart diet-resistant (DR) were fed a chow diet, and their response to D-amphetamine on intracranial self-stimulation and food intake were assessed. The same variables were then evaluated after exposing the rats to a high-fat diet, after DIO rats selectively developed obesity. Finally, gene expression levels of dopamine receptors 1 and 2 as well as tyrosine hydroxylase were measured in reward-related brain regions.

RESULTS

In a pre-obesity state, DIO rats showed innate decreased sensitivity to the reward-enhancing and anorectic effects of D-amphetamine, as compared to DR rats. In a diet-induced obese state, the insensitivity to the potentiating effects of D-amphetamine on intracranial self-stimulation (ICSS) threshold persisted and became more marked in DIO rats, while the anorectic effects were comparable between genotypes. Finally, innate and obesity-induced differences in the gene expression of dopamine receptors were observed.

CONCLUSIONS

Our results demonstrate that brain reward deficits antedate the development of obesity and worsen after obesity is fully developed, suggesting that these alterations represent vulnerability factors for its development. Moreover, our data suggests that the reward-enhancing and anorectic effects of D-amphetamine are dissociable in the context of obesity.

The effects of amphetamine injections on feeding behavior and the brain expression of orexin, CART, tyrosine hydroxylase (TH) and thyrotropin releasing hormone (TRH) in goldfish (Carassius auratus)

In this study, the effects of peripheral (intraperitoneal) injections of D-amphetamine on feeding behavior were assessed in goldfish. Compared with the saline-injected group, amphetamine injections decreased food intake at doses ranging from 1 to 75 μg/g, but not 0.5 μg/g, but increased locomotor behavior, as indicated by the increased number of total feeding and non-feeding acts, at doses ranging from 2.5 to 25 μg/g. Amphetamine at high doses inhibited both food intake (at 25, 50 and 75 μg/g) and feeding behavior (at 75 μg/g). In the hypothalamus, the expression of orexin was down-regulated, and both CART 1 and CART 2 expressions were up-regulated in amphetamine-treated fish (50 μg/g) as compared to saline-injected fish, but amphetamine treatment had no effect on either hypothalamic TH or TRH expression. In the telencephalon, amphetamine treatment (50 μg/g) up-regulated CART 1, CART 2 and TH mRNA expressions but had no effect on either orexin or TRH. Our results suggest that, as in mammals, the orexin, CART and TH systems might be involved in amphetamine-induced feeding/locomotor responses in goldfish.

Serotonin and the regulation of mammalian energy balance

Maintenance of energy balance requires regulation of the amount and timing of food intake. Decades of experiments utilizing pharmacological and later genetic manipulations have demonstrated the importance of serotonin signaling in this regulation. Much progress has been made in recent years in understanding how central nervous system (CNS) serotonin systems acting through a diverse array of serotonin receptors impact feeding behavior and metabolism. Particular attention has been paid to mechanisms through which serotonin impacts energy balance pathways within the hypothalamus. How upstream factors relevant to energy balance regulate the release of hypothalamic serotonin is less clear, but work addressing this issue is underway. Generally, investigation into the central serotonergic regulation of energy balance has had a predominantly “hypothalamocentric” focus, yet non-hypothalamic structures that have been implicated in energy balance regulation also receive serotonergic innervation and express multiple subtypes of serotonin receptors. Moreover, there is a growing appreciation of the diverse mechanisms through which peripheral serotonin impacts energy balance regulation. Clearly, the serotonergic regulation of energy balance is a field characterized by both rapid advances and by an extensive and diverse set of central and peripheral mechanisms yet to be delineated.

Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders

The increased prevalence and high comorbidity of metabolic syndrome (MetS) and mental health disorders (MHDs) have prompted investigation into the potential contributing mechanisms. There is a bidirectional association between MetS and MHDs including schizophrenia, bipolar disorder, depression, anxiety, attention-deficit/hyperactivity disorder, and autism spectrum disorders. Medication side effects and social repercussions are contributing environmental factors, but there are a number of shared underlying neurological and physiological mechanisms that explain the high comorbidity between these two disorders. Inflammation is a state shared by both disorders, and it contributes to disruptions of neuroregulatory systems (including the serotonergic, dopaminergic, and neuropeptide Y systems) as well as dysregulation of the hypothalamic-pituitary-adrenal axis. MetS in pregnant women also exposes the developing fetal brain to inflammatory factors that predispose the offspring to MetS and psychopathologies. Due to the shared nature of these conditions, treatment should address aspects of both mental health and metabolic disorders. Additionally, interventions that can interrupt the transfer of increased risk of the disorders to the next generation need to be developed. © 2013 S. Karger AG, Basel.

Serotonin mediated changes in corticotropin releasing factor mRNA expression and feeding behavior isolated to the hypothalamic paraventricular nuclei

Fenfluramine reduces hunger and promotes body weight loss by increasing central serotonin (5-HT) signaling. More recently, neuropeptides have been linked to the regulation of feeding behavior, metabolism and body weight. To examine possible interactions between 5-HT and neuropeptides in appetite control, fenfluramine (200 nmol/0.5 μl/side) was administered directly into the hypothalamic paraventricular nuclei (PVN) of male rats. Bilateral fenfluramine produced significant hypophagia and increased expression of PVN corticotropin releasing factor (CRF) mRNA and neuropeptide Y (NPY) mRNA in the arcuate nucleus within the first hour after drug administration. Fenfluramine's effects on feeding behavior and mRNA expression were blocked by PVN injections of a 5-HT(1-2) receptor antagonist, metergoline (15 nmol/0.5 μl/side). These data suggest that 5-HT neurons targeting hypothalamic paraventricular CRF neurons may participate in an appetite control circuit for reducing food intake.

Experimental rat models to study the metabolic syndrome

Being the metabolic syndrome a multifactorial condition, it is difficult to find adequate experimental models to study this pathology. The obese Zucker rats, which are homozygous for the fa allele, present abnormalities similar to those seen in human metabolic syndrome and are a widely extended model of insulin resistance. The usefulness of these rats as a model of non-insulin-dependent diabetes mellitus is nevertheless questionable, and they neither can be considered a clear experimental model of hypertension. Some experimental models different from the obese Zucker rats have also been used to study the metabolic syndrome. Some derive from the spontaneously hypertensive rats (SHR). In this context, the most important are the obese SHR, usually named Koletsky rats. Hyperinsulinism, associated with either normal or slightly elevated levels of blood glucose, is present in these animals, but SHR/N-corpulent rats are a more appropriated model of non-insulin-dependent diabetes mellitus. The SHR/NDmc corpulent rats, a subline of SHR/N-corpulent rats, also exhibit metabolic and histopathologic characteristics associated with human metabolic disorders. A new animal model of the metabolic syndrome, stroke-prone-SHR (SHRSP) fatty rats, was obtained by introducing a segment of the mutant leptin receptor gene from the Zucker line heterozygous for the fa gene mutation into the genetic background of the SHRSP. Very recently, it has been developed as a non-obese rat model with hypertension, fatty liver and characteristics of the metabolic syndrome by transgenic overexpression of a sterol-regulatory element-binding protein in the SHR rats. The Wistar Ottawa Karlsburg W rats are also a new strain that develops a nearly complete metabolic syndrome. Moreover, a new experimental model of low-capacity runner rats has also been developed with elevated blood pressure levels together with the other hallmarks of the metabolic syndrome.

Relevance of animal models to human eating disorders and obesity

BACKGROUND AND RATIONALE

This review addresses the role animal models play in contributing to our knowledge about the eating disorders anorexia nervosa (AN) and bulimia nervosa (BN) and obesity.

OBJECTIVES

Explore the usefulness of animal models in complex biobehavioral familial conditions, such as AN, BN, and obesity, that involve interactions among genetic, physiologic, psychological, and cultural factors.

RESULTS AND CONCLUSIONS

The most promising animal model to mimic AN is the activity-based anorexia rodent model leading to pathological weight loss. The paradigm incorporates reward elements of the drive for activity in the presence of an appetite and allows the use of genetically modified animals. For BN, the sham-feeding preparation in rodents equipped with a gastric fistula appears to be best suited to reproduce the postprandial emesis and the defects in satiety. Animal models that incorporate genes linked to behavior and mood may clarify biobehavioral processes underlying AN and BN. By contrast, a relative abundance of animal models has contributed to our understanding of human obesity. Both environmental and genetic determinants of obesity have been modeled in rodents. Here, we consider single gene mutant obesity models, along with models of obesigenic environmental conditions. The contributions of animal models to obesity research are illustrated by their utility for identifying genes linked to human obesity, for elucidating the pathways that regulate body weight and for the identification of potential therapeutic targets. The utility of these models may be further improved by exploring the impact of experimental manipulations on the behavioral determinants of energy balance.

Serotonin and the orchestration of energy balance

The phylogenetically ancient signaling molecule serotonin is found in all species that possess nervous systems and orchestrates diverse behavioral and physiological processes in the service of energy balance. In some instances, the manner in which serotonin signaling influences these processes appears comparable among invertebrate and vertebrate species. Within mammalian species, central nervous system serotonergic signaling influences both behavioral and physiological determinants of energy balance. Within the gastrointestinal tract, serotonin mediates diverse sensory, motor, and secretory functions. Further examinations of serotonergic influences on peripheral organ systems are likely to uncover novel functions consistent with an apparently pervasive association between serotonergic signaling and physiological substrates of energy balance.

Leptin and post-prandial satiety: acute central leptin more potently reduces meal frequency than meal size in the rat

RATIONALE

Many attempts to understand ingestion have sought to clarify the control of meals. Little is known about the effects of the anorexogenic hormone leptin on meal patterning.

OBJECTIVE

The present study sought to perform a dose-response analysis of the effects of acute central leptin administration on meal patterning using a validated, objective meal definition and to compare these results to those obtained with a previously used, subjective meal definition.

METHODS

To validate the objective meal definition pharmacologically, the microstructural effects of the well-studied compound fenfluramine (SC 0, 1, 2, 4 mg/kg) on spontaneous nocturnal intake were determined in mature, non-deprived male Wistar rats (n=8) using a full Latin square design. The effects of intracerebroventricular leptin administration (0, 0.3, 1, 3, 6.25 microg; n=10) were also examined, and perceived meal patterns obtained from the objective and subjective definitions were compared.

RESULTS

Fenfluramine reduced meal size and eating rate at doses that did not reduce meal frequency or duration. In contrast, comparably anorectic doses of leptin had potent post-meal satiety-like effects, reducing meal frequency and prolonging the intermeal interval without reducing average meal size, a finding opposite to that suggested by the previously used subjective meal definition. Unlike comparably and more anorectic doses of fenfluramine, leptin non-specifically reduced both prandial and non-prandial drinking.

CONCLUSIONS

Acute increases in central leptin levels may potently augment post-prandial satiety and influence body-fluid homeostasis. The results reveal unappreciated central modes of action for the ob protein which qualitatively differ from the intra-meal satiating-like effects of fenfluramine.

Human urocortin II, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat

Corticotropin-releasing factor (CRF) has been hypothesized to modulate consummatory behavior through the Type 2 CRF (CRF(2)) receptor. However, behavioral functions subserved by the CRF(2) receptor remain poorly understood. Recently, human urocortin II (hUcn II), a selective CRF(2) receptor agonist, was identified. To study the effects of this neuropeptide on ingestive behavior, we examined the effects of centrally infused hUcn II (i.c.v. 0, 0.01, 0.1, 1.0, 10.0 micro g) on the microstructure of nose-poke responding for food and water in nondeprived, male rats. Malaise-inducing properties of the peptide were monitored using conditioned taste aversion (CTA) testing. To identify potential sites of action, central induction of Fos protein expression was examined. hUcn II dose dependently reduced the quantity and duration of responding for food and water at doses lower (0.01-1.0 micro g) than that forming a CTA (10 micro g). Effects were most evident during hours 4 to 6 of the dark cycle. Meal pattern analysis showed that hUcn II potently (0.1 micro g) increased the satiating value of food. Rats ate and drank smaller and shorter meals without changing meal frequency. Rats also ate more slowly. hUcn II induced Fos in regions involved in visceral sensory processing and autonomic/neuroendocrine regulation and resembling those activated by appetite suppressants. hUcn II is a promising neuropeptide for investigating the role of the CRF(2) receptor in ingestive behavior.

Role of 5-HT1A receptors in the control of food intake in obese Zucker rats of different ages

The present study describes the role of 5-HT1A receptors in the serotonergic control of food intake in obese Zucker rats of different ages. In addition, serotonin (5-HT) and cholecystokinin (CCK) content and 5-HT turnover were determined in various brain regions. The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 100 microg/kg) stimulated food intake in 3-month-old lean control rats but inhibited feeding in obese Zucker rats (300 microg/kg). This pattern remained the same in 6-month-old rats. At 10 months of age, 8-OH-DPAT lost its inhibitory activity in the obese rats but still stimulated feeding in lean controls (300 microg/kg). 5-HT levels were higher in the hypothalamus and in the frontal and parietal cortices of 3-month-old obese Zucker rats and were associated with a lower cortical turnover. In the parietal cortex and the hypothalamus of 6-month-old rats, 5-HT levels were still higher, linked with a lower hypothalamic turnover. No differences were observed in 10-month-old rats. CCK content was not different between obese Zucker rats and lean rats. The persistently different feeding responses to 8-OH-DPAT in obese Zucker rats and lean controls may be related to changes in brain 5-HT metabolism in the obese Zucker rats.

Evidence for the involvement of dopamine D(1) and D(2) receptors in mediating the decrease of food intake during repeated treatment with amphetamine

Repeated treatment with amphetamine (AMPH), a well-known anorectic agent, into animals could induce anorexia on day 1 and produce a gradual reversion of food intake (tolerant anorexia) on the following days. It is unknown whether these feeding changes are related to dopamine (DA) and/or noradrenergic neurotransmission. Thus, the present study investigated the subtype of receptor mediating AMPH-induced anorexia. Daily food intake was measured after various drugs were given. Pretreatment with haloperidol, an antagonist of DA receptors, may lead to inhibition of AMPH-induced anorexia. However, pretreatment with the alpha-adrenoceptor antagonist phentolamine, and the beta-adrenoceptor antagonist propranolol, failed to modify the action of AMPH, suggesting the involvement of DA receptors but not adrenoceptors in the action of AMPH-induced anorexia. Furthermore, pretreatment with SCH 23390 at a dose sufficient to block D(1) receptors or pimozide at a dose sufficient to inhibit D(2) receptors blocked AMPH-induced anorexia, indicating the involvement of D(1) and D(2) receptors. In a study of tolerant anorexia, repeated treatment with the D(1)/D(2) agonist apomorphine, but not the D(1) agonist SKF 38393 or D(2) agonist quinpirole, induced an AMPH-like tolerant feeding response, providing evidence for conjoint action of D(1) and D(2) receptors in the effect. The present results suggest that both D(1) and D(2) receptors are involved in anorexia and tolerant anorexia induced by chronic intermittent administration of AMPH.

Meal-induced changes in extracellular 5-HT in medial hypothalamus of lean (Fa/Fa) and obese (fa/fa) Zucker rats

Hypothalamic serotonin (5-HT) is involved in appetite regulation and sympathetic stimulation of thermogenesis. This study tested the hypothesis that the enhanced energetic efficiency of obese Zucker rats involves blunted serotonergic release within the medial hypothalamus (MH). We used microdialysis and HPLC-EC to measure dynamic changes in extracellular 5-HT levels in the MH of 10-13-week-old male lean (Fa/Fa) and obese (fa/fa) Zucker rats before and after a meal. No differences were noted in basal levels of 5-HT between lean and obese rats. Consistent with the suggestion that hypothalamic 5-HT plays a physiological role in feeding, extracellular 5-HT levels increased significantly in both lean and obese rats given a meal. This increase was observed in the 20 min interval in which they ate the 8.1 kcal meal and remained for an additional 60 min. The net release of 5-HT during the meal interval was comparable in the lean (1.46+/-0.38 fmol/microl) and obese (1.21+/-0.82 fmol/microl) rats. However, the 5-HT levels of the leans (1.80+/-0.29 fmol/microl) plateaued in the next 20 min interval, whereas they continued rising (2.74+/-0.53 fmol/microl) in obese rats and were significantly higher than those in the leans during the 40 and 60 min intervals after the meal was presented. This resulted in a total net release during the meal plus the next three 20 min intervals that was significantly higher in obese (9.83+/-1.16 fmol/microl) than in lean (5.59+/-0.85 fmol/microl) rats. Thus, the enhanced energetic efficiency of the obese Zucker rats may not be associated with attenuated serotonin release in response to a meal. Rather their enhanced release of 5-HT in the MH may reflect compensatory mechanisms for the elevated orexigen NPY, the reduction in meal-induced CCK release, and/or a functional resistance to 5-HT.

Neuropeptide Y mRNA and serotonin innervation in the arcuate nucleus of anorexia mutant mice

The anorexia (anx) mutation causes reduced food intake in preweanling mice, resulting in death from starvation within 3-4 weeks. In wild-type rodents, starvation induces increased neuropeptide Y (NPY) mRNA levels in the arcuate nucleus that promotes compensatory hyperphagia. Despite severely decreased body weight and food intake at 3-weeks age, anx/anx mice do not show elevated NPY mRNA levels in the hypothalamic arcuate nucleus compared to wild-type/heterozygous littermates. The NPY mRNA levels can be upregulated in normal mice at this chronological age, because 24-h food deprivation increased arcuate NPY mRNA in wild-type littermates. The unresponsiveness of NPY expression in the arcuate of anx/anx mice was paralleled by serotonergic hyperinnervation of the arcuate nucleus, comparable to the serotonergic hyperinnervation previously reported in the rest of the anx/anx brain. This result is consistent with the hypothesis that wasting disorders are accompanied by disregulation of NPY mRNA expression in the arcuate nucleus, and suggests that reduced food intake, the primary behavioral phenotype of the anx/anx mouse, may be the result of altered hypothalamic mechanisms that normally regulate feeding.

Changes in the microstructure of feeding after administration of enterostatin into the paraventricular nucleus and the amygdala

The effects of enterostatin (ENT) injected into the paraventricular nucleus (PVN) and the amygdala (AMYG) on the microstructure of feeding was studied by using an automated feeding apparatus. In rats adapted to a 6-h meal feeding regime, ENT reduced the size and duration of the first meal after injection in both the PVN and the AMYG. Similar effects were observed when ENT was given at the beginning of the dark cycle in rats fed ad libitum although the onset of feeding was also delayed in this situation. The number of meals and the size of subsequent meals was unaffected by ENT but the eating rate within the first meal was reduced after ENT injection into the AMYG of meal-fed rats. Enterostatin injected into the AMYG at a dose that suppressed feeding did not produce a conditioned taste aversion. ENT given centrally therefore appears to reduce food intake by delaying the initiation of feeding and/or advancing meal termination suggesting that it affects both appetite and satiation mechanisms.

d-fenfluramine anorexia: dissociation of ingestion rate, meal duration, and meal size effects

In the present study, we ask whether the suppressive effect of d-fenfluramine (d-FEN) on short-term intake can be better explained in terms of a primary action on particular behavioral parameters (e.g., ingestion rate or meal duration), as proposed by several investigators, or in terms of a primary effect on an intake "target" that can be achieved via diverse behavioral strategies. We applied two specialized intake testing paradigms that constrain the behavioral structure of the rat's meal in different ways, and determined whether or not the meal-size result varied in turn. (1) In the intraoral intake test, the rate of ingestion was clamped by the rate (1.0 ml/min) at which the test stimulus (12.5% glucose) was intraorally delivered. A d-FEN (3 mg/kg) suppression of intraoral intake was obtained demonstrating that ingestion rate adjustment is not necessary for the anorexic effect. In addition, for both d-FEN and vehicle conditions, comparable amounts were consumed when the intraoral intake test was either continuous or interrupted for 10 min beginning 6 min after test onset. For d-FEN, the increase in meal duration (mean = 11.98 min) required to compensate for the imposed interruption indicates that the drug does not specify an absolute limit for meal duration. (2) In the drop size-controlled spout-licking test, the volume of 12.5% glucose delivered for each lick was fixed at either 8 or 4 microliters. There was an overall reduction in intake with d-FEN (0.75 mg/kg), but as under vehicle injection conditions, the number of licks emitted approximately doubled when lick volume was halved. As a result, meal size was unaffected by the drop size manipulation. The drop size manipulation affected several other behavioral parameters under respective d-FEN and vehicle injection conditions, including: average rate of ingestion (ml/min), initial ingestion rate, and ingestion duration (meal duration minus pause time). The two experiments together demonstrate that the anorexic effect of d-FEN does not depend on adjustment of any particular behavioral parameter. The results suggest, rather, that given doses of d-FEN establish a particular degree of intake suppression that the rat defends via diverse behavioral strategies.

Appetite-suppressing effects of urocortin, a CRF-related neuropeptide

The neuropeptide corticotropin-releasing factor (CRF) is well known to act on the central nervous system in ways that mimic stress and result in decreases in exploration, increases in sympathetic activity, decreases in parasympathetic outflow, and decreases in appetitive behavior. Urocortin, a neuropeptide related to CRF, binds with high affinity to the CRF2 receptor, is more potent than CRF in suppressing appetite, but is less potent than CRF in producing anxiety-like effects and activation. Doses as low as 10 nanograms injected intracerebroventricularly were effective in decreasing food intake in food-deprived and free-feeding rats. These results suggest that urocortin may be an endogenous CRF-like factor in the brain responsible for the effects of stress on appetite.

Individual differences in sugar consumption following systemic or intraaccumbens administration of low doses of amphetamine in nondeprived rats

Rats exhibit individual differences in their propensity to ingest sucrose and in their feeding response to low doses of amphetamine (AMP). Rats with high baseline sugar intake (HIGH) show a decrease in sugar consumption in response to AMP, while rats with low baseline sugar intake (LOW) show an increase in consumption (33,34). At present, it is not known whether LOW and HIGH rats would be differentially responsive to higher, anorexigenic doses of AMP. Thus, the present study was developed to further determine the dose-response curve for AMP's effects on sugar consumption in LOW and HIGH rats. One group of rats received IP injections of 0.05, 0.1, and 0.2 mg/kg AMP, while a second group was administered 0.25, 0.5, and 1.0 mg/kg AMP. A third group of rats received intranucleus accumbens (Acc) microinjections of low to moderate (2.0-8.0 micrograms) doses of AMP, because evidence indicates that this may be an important site of action for AMP's effects on feeding in LOW and HIGH rats. Results showed that at low doses (< or = 0.25 mg/kg), AMP stimulated sugar consumption in LOW rats and either had no effect or inhibited consumption in HIGH rats. At doses greater than 0.25 mg/kg, AMP inhibited sugar consumption in both LOW and HIGH rats. Furthermore, intra-Acc administration of AMP stimulated sugar intake in LOW rats and produced a slight, but nonsignificant, decrease in consumption in HIGH rats. Taken together, these results show that LOW and HIGH rats exhibit individual differences in their feeding response to low but not moderate to high doses of AMP. Furthermore, the evidence indicates that the Ace is an important site for AMP's facilitatory effect on sugar consumption in LOW rats.

Serotonergic control of the organization of feeding and satiety

Studies in which serotonergic drugs were administered either systemically or directly into central sites have implicated 5-HT in the inhibitory control of feeding in mammals. In animal models and in humans, 5-HT agonists such as fenfluramine, fluoxetine and sertraline reduced the rate of eating and the size of meals in a manner suggesting that increasing serotonergic neurotransmission specifically enhanced satiation. In rodents, directly acting agonists at 5-HT1B, 5-HT2C or 5-HT2A receptors decreased food intake but by different behavioral mechanisms. Stimulation of the 1B and 2C subtypes may probe physiological roles in feeding and satiety. The former receptors may be involved primarily in regulating meal size and the latter more in controlling eating rate. Activation of both may be required for complete expression of behavioral satiety. By contrast, stimulating 2A sites may simply disrupt the continuity of feeding. Drugs that stimulate 5-HT1A autoreceptors increase food intake, presumably by acutely reducing the firing of serotonergic neurons in the brain. The hypothalamic paraventricular nucleus (PVN) has been proposed as an important terminal field in the forebrain that is involved in 5-HT's satiety role although recent studies implicate extra-PVN regions in this function. Peripherally administered 5-HT also decreases food intake in rats in a behaviorally specific manner. Studies with antagonists and with structural analogs of 5-HT revealed that 5-HT's peripheral satiety action involves 5-HT1-like and 5-HT2-like mechanisms. Thus, within and outside the brain, multiple pharmacological and behavioral mechanisms contribute to serotonergic functions in ingestion. The rich body of data from preclinical investigation in animals provides the foundation for therapeutic development in humans.

Time cost of alternation reduced demand for food in a closed economy

A principal purpose of the present study was to characterize rats' demand for food by increasing the required delay between the alternation of leverpresses. While living in cages that were exposed to a 12:12 light:dark cycle, rats were required to alternate leverpresses for their entire daily food ration. After a press on one lever resulted in the delivery of a food pellet, a red cuelight was illuminated for a fixed duration that equaled the imposed delay between successive leverpresses. After the imposed delay elapsed and the cuelight was turned off, a press on the alternate lever resulted in the delivery of another food pellet. Increases in the imposed delay from 0.01 s to 16 s reduced mean percent correct (alternation) and mean food intake, although both were reduced more rapidly and to a greater extent in the light than in the dark photoperiod. This interaction resulted from a reduction of meal size in the light and a compensatory increase in meal size in the dark as the imposed delay increased. Rats also defended their daily intake in the dark against increasingly larger imposed delays by spending increasingly larger amounts of time alternating and by increasing total (correct + incorrect) presses. These results suggest that photoperiod is a determinant of the motivational value of food as a reinforcer for instrumental behavior in a closed economy.

Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors

The present paper provides an overview of dopamine (DA) and cholecystokinin (CCK) mechanisms that contribute to psychostimulant reward-related behaviors. Three different behavioral paradigms are focused on: intravenous psychostimulant reward, psychostimulant-induced locomotor activity, and psychostimulant-induced feeding. Based on evidence derived from these different behavioral paradigms, this paper reviews data indicating that nucleus accumbens CCK and DA play an important role in mediating reward. Neurobiological mechanisms are proposed to explain the functional relationship between CCK and DA in the nucleus accumbens.

Effects of serotonin and the serotonin blocker metergoline on meal patterns and macronutrient selection

Serotonin [5-hydroxytryptamine(5-HT)] in the paraventricular nucleus (PVN) of rats has a suppressive effect on feeding behavior and causes a selective decrease in carbohydrate ingestion, specifically at the onset of the natural (dark) feeding period. Studies conducted here provide further evidence for this phenomena, showing a similar dose-related decrease in carbohydrate ingestion at dark onset after PVN injection of 5-HT or of the agonists, d-norfenfluramine or fluoxetine, which act through endogenous 5-HT. To further characterize the effects of this indoleamine on the macrostructure of feeding, a computer-automated data acquisition system was used to analyze macronutrient feeding patterns in freely feeding animals maintained on the pure diets of protein, carbohydrate, and fat. Results indicate that PVN administration of 5-HT at dark onset decreases intake of the carbohydrate nutrient by decreasing meal size, feeding time, and feeding rate for this nutrient and increasing the satiating effect of carbohydrate. These effects, which occur specifically during the first meal after injection, are opposite those seen after peripheral administration of the 5-HT receptor antagonist, metergoline. This drug stimulates feeding through a selective increase in carbohydrate intake, characterized by an increase in meal size, percent composition, and feeding time for this nutrient and a decrease in the satiety ratio for carbohydrate. These results implicate the serotonergic system in the termination of carbohydrate-rich meals that are prevalent during the early hours of the natural feeding cycle.

Individual differences in the feeding effects of amphetamine: role of nucleus accumbens dopamine and circadian factors

Evidence indicates that amphetamine (AMP) affects feeding in a baseline-dependent fashion and that the nucleus accumbens (Acc) is an important site of action for AMP's effects on feeding. Experiment 1 examined the contribution of Acc-dopamine (DA) mechanisms to the baseline-dependent feeding effects of a 0.125 mg/kg dose of AMP using intra-Acc administrations of cis-flupenthixol (FLU). Results showed that there was an inverse relation to AMP, such that AMP stimulated feeding in animals with high baseline intake. Intra-Ace FLU administration reversed the stimulatory but not the inhibitory effect of AMP. Further, intra-Acc FLU attenuated baseline feeding in high but not low baseline feeders. Experiment 2 sought to determine whether AMP would affect feeding in a baseline-dependent manner when administered in the dark photoperiod of the rat circadian cycle, when rats do most of their feeding. To this end, rats were administered three doses (0.05,0.01, and 0.25 mg/kg) of AMP in the dark photoperiod and the intake of sugar monitored. Results showed that in low baseline feeders, AMP stimulated intake at lowest dose and had no effect at higher doses. In high baseline feeders, AMP inhibited intake in a dose-dependent manner. Taken together, these results further establish that AMP affects feeding in a baseline-dependent fashion. Moreover, the similar effects of AMP across the light and dark photoperiods suggest that a straightforward rate-dependency interpretation is not adequate. Finally, it is speculated that Acc-DAergic activity may play a role in the observed differences in baseline intake levels and in the response to AMP.

Feeding pattern studies suggest that d-fenfluramine and sertraline specifically enhance the state of satiety in rats

The effects of d-fenfluramine (1.5 mg/kg) and sertraline (10 mg/kg), administered intraperitoneally once daily for seven days were studied on feeding parameters of rats over various periods. On the first day of treatment both drugs markedly reduced meal size and meal duration during the first hour and, to a lesser extent, the first 4 h. No effects were seen later. The size and duration of eating bouts were also markedly reduced by both drugs in the first hour. There was no significant effect of either drug on meal frequency in any period. Only d-fenfluramine significantly reduced the rate of eating within 4 h from the start of testing. Sertraline, but not d-fenfluramine, markedly increased locomotor activity in the first 4 h after the start of testing. The d-fenfluramine effect on eating rate disappeared by the second day whereas total intake and meal size were still reduced on day five. By days six and seven however the d-fenfluramine-treated rats did not differ from the controls. During the seven-day treatment sertraline always reduced total food eaten and meal size but caused only transient changes of locomotor activity and eating rate. Since the effects of d-fenfluramine and sertraline on meal size and food intake could be separated from the effects on eating rate and arousal, it appears that at appropriate doses these drugs specifically increase the satiating effect of food. Tolerance to this effect appears to develop more rapidly for d-fenfluramine than for sertraline.

Facilitation and inhibition of feeding by a single dose of amphetamine: relationship to baseline intake and accumbens cholecystokinin

Amphetamine (AMP) administered in high doses suppresses feeding. However, in low doses AMP has been shown to both suppress and facilitate feeding. Further, there is some indication of individual differences in the feeding response to low doses of AMP. Evidence indicates that AMP's effects on feeding are dopamine-mediated and that the nucleus accumbens (Acb) may be an important site of action. Of interest here is the fact that CCK terminals exist within the Acb and CCK modulates DA activity. Experiment 1 investigated the effects of intra-Acb CCK administration as a function of individual differences in the feeding response to a low dose of systemic AMP. Results indicate that response to AMP was baseline dependent. AMP stimulated feeding in low baseline feeders and suppressed feeding in high baseline feeders. Intra-Acb CCK blocked the AMP-induced increase in feeding but not the AMP-induced anorexia. In experiment 2, the effects of intra-Acb CCK administration on baseline feeding were assessed. Intra-Acb CCK suppressed baseline feeding, but only when there was a high level of intake. It is speculated that Acb-DAergic activity may play a role in the observed feeding effects of both AMP and CCK.

Effect of fenfluramine on prolactin and thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in obese and normal women

In order to demonstrate the suggested failure of the serotoninergic system in human obesity and to evaluate the role of central serotoninergic activity in prolactin (PRL) and thyroid stimulating hormone (TSH) release in this condition, 13 euthyroid obese and 9 healthy women of normal weight were studied. A TRH test (200 micrograms i.v.) was performed before and after administration of fenfluramine (FF) 60 mg b.d. for 14 days. In the controls, FF did not modify the expected significant increase in PRL induced by TRH. In obese patients, however, the PRL levels was significantly increased after TRH, but the increase was less than in the controls. After FF, the PRL response to TRH was larger than in the pretreatment phase, with values similar to those observed in normal subjects. In neither group FF did change the TSH-stimulating effect of TRH, but the hormonal response in obese patients was greater than in the controls. The restoration of the responsiveness of PRL to TRH after central serotoninergic stimulation confirms the hypothesis that a failure of the serotoninergic system may occur in human obesity. Since FF does not interfere with the secretory pattern of basal and stimulated TSH in normal or obese subjects, the serotoninergic system does not seem to play a major role in the control of TSH secretion.

Amphetamine- and morphine-induced feeding: evidence for involvement of reward mechanisms

The present study examined the possibility that the increased feeding found following central and peripheral administrations of low doses of d-amphetamine (AMP) and morphine (MOR) may involve central reward mechanisms. In order to examine this possibility, the effects of these drugs on food selection and intake of foods that varied in palatability and nutritive content were determined. In addition, the importance of the nucleus accumbens (ACB), a critical structure for AMP and MOR reward, in these effects was determined. Results indicated that MOR increased the intake of preferred food regardless of nutritive content. In contrast, AMP was most effective at increasing the intake of preferred foods which contained carbohydrates. These effects were observed following systematic or intra-ACB administration of low doses of MOR and AMP. Together these findings implicate reward mechanisms in the expression of MOR- and AMP-induced feeding. It is further suggested that the feeding effects of MOR and AMP can be differentiated in paradigms where animals have a choice of several foods which may vary in palatability and/or nutritive content. The relevance of the present findings for our understanding of which elements of food and feeding behavior are coupled with ACB reward signals is also discussed.

A behavioural profile of fluoxetine-induced anorexia

Fluoxetine is a specific and long-lasting inhibitor of serotonin reuptake. In free-feeding rats a dose of 10 mg/kg reduced meal size but had no significant effect on meal frequency. Feeding rate during meals was also reduced. Direct observation of behaviour associated with eating suggested that fluoxetine did not act by enhancing sleep or other behaviour patterns that interfere with eating, although the transition from feeding to sleep occurred more rapidly after drug treatment. Enhancement of satiety or interference with the sustaining of meals by fluoxetine would be consistent with these data. Rebound feeding after anorexia was not observed in either the meal pattern study or in a separate experiment using schedule fed animals. There was also no clear development of tolerance to the anorectic effect of fluoxetine, and we discuss possible reasons for an association of these two properties.

Food intake in baboons: effects of d-amphetamine and fenfluramine

Food intake of four adult male baboons (Papio c. anubis) was monitored during daily experimental sessions lasting 22 hours. Food was available under a two-component operant schedule. Following completion of the first "procurement component" response requirement, access to food, i.e., a meal, became available under the second "consumption component" during which each response produced a one-g food pellet. After a 10-minute interval in which no response occurred, the consumption component was terminated. The effects of oral d-amphetamine (AMPH: 0.03-1.0 mg/kg) and fenfluramine (FEN: 0.25-2.0 mg/kg) were determined by having the baboons drink a dose on Tuesdays and Fridays 45 to 60 min before the daily session. Dose-dependent decreases in food intake were observed with AMPH being four times as potent as FEN. Although both drugs were equally efficacious in decreasing food intake, they had dissimilar effects on the topography of feeding behavior. AMPH decreased food intake by increasing the latency to the first meal, decreasing the size of the first meal, and decreasing the number of meals within a session. FEN, in contrast, had no significant effect on latency to the first meal or size of the first meal, but decreased the number of meals within a session. In addition, the drugs had different effects on the patterning of responding within the first meal. Finally, at the doses tested, there was no evidence of nonspecific motor deficits disrupting food intake. Although there are some differences between these results and the previously reported effects of these drugs, it is clear that AMPH and FEN influence feeding behavior in different ways.

The effects of the kappa agonist PD-117302 on feeding behaviour in obese and lean Zucker rats

It has been suggested that super-sensitivity to, or overactivity of, endogenous opioid systems, particularly the dynorphin system, may be important in the development of obesity in the obese mouse (ob/ob). We have investigated the possibility that an increase in sensitivity to kappa agonists may also play a role in the development of obesity in another mutant rodent, the Zucker rat. The effects of the selective kappa agonist PD-117302 were investigated in both lean and obese Zucker rats. The lean animals appeared to be more sensitive to the initial hyperphagic effects of PD-117302 than their obese littermates, although this initial hyperphagia was followed by a subsequent decrease in food intake so that by the end of the six-hour test period the animals treated with PD-117302 had eaten less than the saline-treated controls. These changes in food intake were paralleled by increases and decreases in the duration of time spent feeding throughout the experiment. At the doses used in this study PD-117302 had no effect on locomotor activity. It is concluded that obese Zucker rats are not more sensitive to the hyperphagic effects of the kappa agonist (PD-117302 than their lean littermates and therefore it seems unlikely that increased sensitivity to an endogenous kappa opioid system plays a major part in the overeating and obesity observed in this strain of rat.

The effects of d-fenfluramine on saccharin intake and preference, and on food and water intake

The effects of d-fenfluramine on saccharin intake and preference were examined to investigate whether the reduced rate of eating induced by this compound reflects a reduction in the palatability of foods. In two separate experiments, water deprived rats were offered a choice between a 0.05% solution of saccharin and water, or a 0.2% saccharin solution and water. Injection of d-fenfluramine at doses which reliably decreased food intake resulted in dose dependent reductions in total fluid intake and saccharin intake. A trend towards reduced water intake was observed also, and this together with the reduced saccharin intake resulted in no overall change in saccharin preference. In a further experiment, d-fenfluramine reduced the water intake of water deprived rats to the same extent as it reduced total fluid intake in the choice tests. Since d-fenfluramine failed to alter saccharin preference, it is unlikely that the slowed eating rate induced by this compound indicates a reduction in food palatability. Instead, it is likely that this behaviour results from a subtle motor deficit, such that fenfluramine treated animals are unable to maintain ingestion at the same rate as non-drugged animals. This explanation could account for the reduction in the consumption of non-nutritive saccharin solutions and water in water deprived animals. The relevance of this action to the anorectic effect of fenfluramine is discussed.

Hyperinsulinemia of the genetically obese (fa/fa) rat is decreased by a low dose of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)

Changes in glycemia and insulinemia were determined in conscious lean (FA/?) and obese (fa/fa) rats after acute administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). The intravenous injection of a low dose of 8-OH-DPAT (150 micrograms/kg) to lean rats rapidly promoted hyperglycemia. This modification was associated with a slight increase in insulinemia. The injection of 8-OH-DPAT markedly decreased basal hyperinsulinemia in obese rats while inducing hyperglycemia. Further evidence of the strong inhibitory effect of 8-OH-DPAT on insulin release was obtained in lean and obese rats during glucose tolerance tests. Intracerebroventricular injection of 8-OH-DPAT (45 micrograms/animal) triggered hyperglycemia and markedly decreased insulinemia in both lean and obese rats. This hypoinsulinemic effect of 8-OH-DPAT was more pronounced in the obese than in the lean animals. Measurement of the food intake elicited by 8-OH-DPAT (500 micrograms/kg s.c.) showed that the hyperphagic action of the 5-HT1A agonist was the same in FA/? and fa/fa rats. It is suggested that: (i) hyperinsulinemia of the genetically obese rat may be diminished by a low dose of 8-OH-DPAT; (ii) 5-HT1A autoreceptor-mediated regulation of serotonergic activity is not different in lean (FA/?) and obese (fa/fa) rats; (iii) 8-OH-DPAT could be of potential therapeutic use for some aspects of the pathology of type II diabetes.

Effects of d- and l-amphetamine on food intake: evidence for a dopaminergic substrate

The present experiment examined the effects of d- and l-amphetamine on the intake of sugar, sweetened rat chow and unsweetened rat chow in free feeding rats. Rats were injected IP with 4 doses of d- or l-amphetamine (0.0, 0.125, 0.50 and 2.00 mg/kg). Regardless of drug condition, animals were found to prefer sugar over sweetened or unsweetened chow. d-Amphetamine significantly increased food intake at 0.125 and 0.50 mg/kg doses but not at 2.00 mg/kg. l-Amphetamine had no significant effects at any dose. Further, d-amphetamine significantly increased sugar intake but not sweetened or unsweetened chow. Since d- and l-amphetamine are equipotent at releasing noradrenaline, while d-amphetamine is 2 to 5 times more potent at releasing dopamine, the results suggest that d-amphetamine-induced feeding is associated with activation of a dopaminergic substrate.

Effects of naloxone and naltrexone on meal patterns of freely-feeding rats

The effects of naloxone and naltrexone on the night-time meal patterning of freely-feeding male rats were investigated using a Kissileff-type eatometer. Naloxone (5.0 mg/kg) and naltrexone (2.5 mg/kg) reduced intake for two hours after IP injection. This effect resulted from a shortening of duration of meals and an extension of postmeal intervals. Unlike other anorexic agents neither drug affected meal frequency or the eating rate within meals. These particular opioid antagonists therefore appear to produce anorexia by advancing meal termination and extending the inhibition of feeding which follows a meal. These specific changes in the structure of the meal pattern consolidate previous findings and support the hypothesis that naloxone and naltrexone reduce food intake in rats by promoting satiation and prolonging satiety.

Experimental manipulations of eating: advances in animal models for studying anorectic agents

The material set out in this text has been designed to show the wide range of procedures which have the capacity to modify eating behavior--to produce hyper- or hypophagia, to alter the profile of eating patterns, or to adjust dietary preferences and selection. Accordingly, in investigating anorectic drugs it seems necessary to observe the effects of drug actions in a variety of experimental models. This strategy will provide a more complete description of the effect of a drug, will throw light on the mechanism of action, and will provide a more realistic base for predicting the effects of drugs in man.

Medial hypothalamic serotonin: effects on deprivation and norepinephrine-induced eating

Evidence to date suggests an inhibitory role for serotonin (5-HT) in the regulation of feeding behavior. In the present study, hypothalamic 5-HT was investigated for its anorexic potency under different feeding conditions. In fasted rats, 5-HT (1.1-4.4 micrograms) injected into the hypothalamic paraventricular nucleus (PVN), produced a reliable dose-dependent reduction in food consumption. Under satiated conditions, this inhibitory effect was significantly larger and apparent at lower doses (down to 0.1 micrograms), in animals induced to eat by PVN injection of norepinephrine (NE). Tests with receptor antagonists, injected into the PVN immediately prior to 5-HT, revealed a dose-dependent blockade of 5-HT's action by the serotonergic blockers, metergoline, methysergide and cinanserin. While the effect of 5-HT was somewhat attenuated by administration of certain beta-adrenergic and phenothiazine-type dopamine receptor antagonists, 5-HT was totally resistant to the actions of more selective dopamine blockers and of the cholinergic and histaminergic antagonists, atropine and dexbrompheniramine. PVN injection of various serotonergic compounds, known to inhibit feeding when peripherally administered, also suppressed NE-induced feeding in a dose-related manner (fluoxetine = dl-norfenfluramine greater than quipazine greater than chlorimipramine greater than dl-fenfluramine). Further tests with PVN administration of the dextro isomer and metabolite of fenfluramine showed a considerably stronger inhibitory effect with d-norfenfluramine as compared to dexfenfluramine, and a particular effectiveness of peripherally injected dexfenfluramine in NE-injected rats, at doses at least 10-fold higher than centrally effective doses.(ABSTRACT TRUNCATED AT 250 WORDS)

Hypothalamic serotonin in the control of meal patterns and macronutrient selection

Serotonin (5-HT) is believed to have an inhibitory influence over feeding behavior. The present experiments were designed to investigate the effects of hypothalamic 5-HT on spontaneously motivated feeding and appetite regulation. Freely-feeding rats were injected with 5-HT or norfenfluramine (NORFENF) directly into the paraventricular hypothalamus (PVN), and precise changes in feeding behavior were monitored by a computer. Following PVN 5-HT or NORFENF injection, animals exhibited a marked suppression in food intake, associated with a decrease in meal size, duration and eating rate, and no change in the frequency of meals consumed. This suggests that brain 5-HT may influence primarily the induction of satiety rather than the suppression of hunger. The effect of drugs presumed to affect brain 5-HT transmission on diet selection was also investigated in groups of rats injected centrally with 5-HT or NORFENF or peripherally with either fenfluramine, quipazine or cyproheptadine. In a series of 2-diet tests, rats centrally injected with 5-HT or NORFENF exhibited a selective suppression of the carbohydrate-rich diets. In animals provided with three pure macronutrient diets, protein, carbohydrate, and fat, systemic administration of serotonergic agents had its greatest impact on fat and carbohydrate ingestion, as compared to protein consumption. These findings support a role for hypothalamic 5-HT in modulating meal patterns and appetite for particular macronutrients.

Amphetamine: effects on meal patterns and macronutrient selection

Catecholaminergic systems, specifically in the region of the lateral perifornical hypothalamus (PFH), have been linked to the inhibition of feeding behavior. The present studies examined the effects of d-amphetamine (AMPH), which is believed to act through the release of endogenous catecholamines (CAs), on spontaneous feeding and appetite regulation in rats. Injection of AMPH directly into the PFH caused a marked suppression of food intake; changes in computer-monitored meal patterns were characterized by an increase in the latency to meal onset and a consequent reduction in meal size and duration. This suggests that hypothalamic AMPH administration may influence primarily the initiation, rather than the termination, of feeding. In other experiments, chronic infusion of AMPH directly into the PFH was shown to suppress 24 hr food intake and body weight gain, indicating the effectiveness of lateral hypothalamic CA stimulation in overriding normal long-term patterns of feeding. The effect of hypothalamic CA stimulation on macronutrient selection was also investigated in groups of rats injected either centrally or peripherally with AMPH, or centrally with the CA agonists, dopamine and epinephrine. Each of these manipulations caused a strong inhibition of protein intake with no effect on carbohydrate, and only a mild suppression of fat ingestion after peripheral AMPH. These selective effects of AMPH on feeding patterns and diet choice, provide support for a role of CA innervation to the lateral hypothalamus in the modulation of natural feeding behavior and macronutrient selection.

Fenfluramine discrimination in obese and lean Zucker rats: serotonergic mediation of effect

Genetically obese Zucker rats and their lean littermates were trained to discriminate between the stimulus properties of 2.0 mg/kg fenfluramine and its vehicle in a two-lever, food-motivated operant task. Both groups learned the discrimination at the same rate and all rats showed a dose-related decrease in discriminative performance with lower fenfluramine doses. Analysis of the dose-response curves indicated an ED50 for the obese rats of 0.56 mg/kg and for the lean group of 0.42 mg/kg. Time-course experiments indicted that the obese rats maintain errorless discrimination through 90 min post-injection but discriminate significantly less than the lean rats at 960 min post-administration. These results suggest a similar sensitivity to fenfluramine in obese and lean rats with a difference in the time-course of drug action. Pre-treatment with the specific serotonin receptor antagonist pirenperone significantly attenuated fenfluramine discrimination in lean rats without a similar effect in the obese rats. Possible reasons for this observation are offered.

Brain serotonin and eating behavior

Studies indicate that hypothalamic monoamine systems involved in the control of food intake have specific effects on temporal feeding patterns and on appetite for specific macronutrients. Based on the evidence obtained in rats, it is proposed that serotonin acts, in part, through a satiety mechanism of the medial hypothalamus, to reduce ingestion of carbohydrate while sparing protein intake. In controlling the ratio of carbohydrate to protein intake, this serotonergic system, which is responsive to the anorectic agent fenfluramine, is believed to function in direct opposition to the alpha 2-noradrenergic system of the paraventricular nucleus, which inhibits satiety for carbohydrate and thereby potentiates the size of carbohydrate meals. This serotonergic system may also indirectly oppose the catecholaminergic systems of the lateral hypothalamus, which mediate amphetamine anorexia and which inhibit a hunger-stimulating system for protein intake, thereby delaying the initiation of protein meals. Examination of the rats' normal eating patterns, in conjunction with particular biochemical analyses, has indicated specific points in the circadian eating cycle where these hypothalamic monoamine systems, in association with changes in circulating hormones and nutrients, may be physiologically activated.

Gastromotor mechanism of fenfluramine anorexia

A gastric slowing effect of fenfluramine accounts for most of the drug's suppressant effect on food intake in freely feeding rats. It is conceivable on the evidence to date that this gastromotor action of fenfluramine explains all its effects on appetite and metabolism, but additional peripheral and central effects--such as motor inhibition--are likely. Rate of gastric emptying is quantitatively the dominant physiological control of appetite: it determines the duration for which absorption of a meal sustains metabolic satiety; it also influences gastric distension, which can be a source of innate satiation and of learned carbohydrate-specific satiation. Since most of the neurotransmitter serotonin (5HT) resides in the gastrointestinal wall, not the brain, gastromotor suppression of appetite should be the first working hypothesis for a serotoninergic drug such as fenfluramine. The largest effect on food intake that arises from gastric slowing by fenfluramine and active metabolites is a lengthening of the period of satiety after a meal of a given size. The residue of this extended satiety could reduce appetite at a subsequent fixed mealtime and hence the size of such a meal. Fenfluramine appears not to intensify satiation processes generated by a meal. Rather, it affects eating processes from the start. Also, fenfluramine disrupts learned carbohydrate-specific satiation operative within a meal. This negates the claim that fenfluramine reduces carbohydrate-specific appetite--which in any case (like other claims that drugs modulate nutrient selection) is not based on adequately designed dietary selection tests.

Serotonin manipulations and the structure of feeding behaviour

Experimental manipulations of 5-HT by central or peripheral procedures produce clear effects on food intake. Interpretation of these effects can be improved by monitoring changes in the behavioural structure of feeding and by designing experiments which adjust the contextual and temporal dimensions of feeding. Experimental techniques include micro-analysis of behaviour, macro-analysis of meal patterns, dietary self-selection of macro-nutrients, analysis of appetite and satiety sequences, appetitive and consummatory aspects of instrumental performance and dietary-induced hyperphagia. Using these procedures in conjunction with various pharmacological treatments including the administration of tryptophan, 5-hydroxy-tryptophan, 5-HT, re-uptake blockers, synaptic releasers, synthesis blockers, receptor blockers and others it has been demonstrated that 5-HT manipulations give rise to a specific constellation of changes in feeding parameters. The most prominent changes following peripheral or central (paraventricular nucleus) injections are a reduction in meal size and a curtailment of eating rate. These changes can be distinguished from those induced by other pharmacological treatments and are consistent with a modulation of the process of satiation and the state of satiety. Changes in feeding induced by 5-HT manipulations are not secondary to non-specific behavioural alterations.